We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+9.28%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$612M
AUM Growth
-$64.3M
Cap. Flow
-$69.2M
Cap. Flow %
-11.31%
Top 10 Hldgs %
55.01%
Holding
54
New
9
Increased
9
Reduced
21
Closed
8

Top Buys

1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$14.4M
2
IART icon
Integra LifeSciences
IART
+$12.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$12.1M
4
MDCO
Medicines Co
MDCO
+$11.3M
5
ADMA icon
ADMA Biologics
ADMA
+$3.08M

Top Sells

1
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
2
CORI
Corium International, Inc.
CORI
+$10.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$9.16M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.72M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$6.07M

Sector Composition

1 Healthcare 91.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
51
CALL
DELISTED
Aerie Pharmaceuticals
AERI
– –
-150,000
Closed -$7.29M
AERI
52
DELISTED
Aerie Pharmaceuticals
AERI
– –
-64,800
Closed -$3.15M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Broadfin Capital held 54 positions worth $612M, down 9.5% from $676M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $69.2M in Q4 2017, closing 8 positions and reducing 21 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $8.72M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $16.2M.

  • Broadfin Capital's largest Q4 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 122,930 shares worth $16.2M.
  • Broadfin Capital added most to Integra LifeSciences in Q4 2017, an estimated $12.3M increase.
  • Broadfin Capital's biggest Q4 2017 reduction was Heron Therapeutics, cutting an estimated $23.3M.
  • Broadfin Capital fully exited Alnylam Pharmaceuticals in Q4 2017, selling an estimated $8.72M.
  • Broadfin Capital's ten largest holdings make up 55% of its $612M portfolio in Q4 2017.
  • Broadfin Capital opened 9 new positions and closed 8 in Q4 2017.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $612M.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.